<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Albrektsen Finnegan | Activity</title>
	<link>https://www.catswannabecats.com/members/bootbrown98/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/bootbrown98/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Albrektsen Finnegan.</description>
	<lastBuildDate>Wed, 01 Jul 2026 18:37:05 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">d31802c7eeb8d3b916e0d03eada74e83</guid>
				<title>Albrektsen Finnegan posted an update: Herein, we report the identification and preclinical profile [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23371/</link>
				<pubDate>Sun, 08 Jun 2025 09:01:06 -0400</pubDate>

									<content:encoded><![CDATA[<p>Herein, we report the identification and preclinical profile of a lead compound 10, (SPR519) as an equally potent dual inhibitor of PI3Kα and mTOR kinases. SPR519 exhibits an EC50 of low sub-micromolar range among various tested cancer cell lines such as A2780 (0.23 μM), PC3 (0.48 μM), and SKOV3 (0.50 μM). When administrated orally, it shows a con&hellip;<span class="activity-read-more" id="activity-read-more-23371"><a href="https://www.catswannabecats.com/activity/p/23371/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">062f39b18f28083bdba0f621e0e76983</guid>
				<title>Albrektsen Finnegan posted an update: 0001).In patients with early ISR lesions, the LDL-C levels [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/19683/</link>
				<pubDate>Thu, 05 Jun 2025 09:10:43 -0400</pubDate>

									<content:encoded><![CDATA[<p>0001).In patients with early ISR lesions, the LDL-C levels may be related to the formation and progression of early neoatherosclerosis, and poor LDL-C control may be a risk factor for the occurrence of early-stage neoatherosclerosis following DES implantation.Previous study has identified marked differences in patient characteristics and causes of&hellip;<span class="activity-read-more" id="activity-read-more-19683"><a href="https://www.catswannabecats.com/activity/p/19683/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d9121edf45d06ffb3beeff381a48b389</guid>
				<title>Albrektsen Finnegan posted an update: One of the most pressing challenges in the clinical research [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/17761/</link>
				<pubDate>Tue, 03 Jun 2025 09:09:20 -0400</pubDate>

									<content:encoded><![CDATA[<p>One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a&hellip;<span class="activity-read-more" id="activity-read-more-17761"><a href="https://www.catswannabecats.com/activity/p/17761/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d1c5c873a517fbd5d8ceb206e881775e</guid>
				<title>Albrektsen Finnegan posted an update: Based on these results, we propose a novel model where RAD9 [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/12137/</link>
				<pubDate>Sun, 01 Jun 2025 08:51:15 -0400</pubDate>

									<content:encoded><![CDATA[<p>Based on these results, we propose a novel model where RAD9 is regulated epigenetically by DNMT1 and DNMT3B, via targeted hypermethylation, and that consequent RAD9 overproduction promotes prostate tumorigenesis.Cervical cancer (CC) is the fourth most common cancer in women; the survival rates depend strongly on its early detection. The Pap test&hellip;<span class="activity-read-more" id="activity-read-more-12137"><a href="https://www.catswannabecats.com/activity/p/12137/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8ff82c07f852617540cfa9c056b94f65</guid>
				<title>Albrektsen Finnegan posted an update: The aim of this study was to assess the sensitivity of [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/9569/</link>
				<pubDate>Sat, 31 May 2025 22:51:41 -0400</pubDate>

									<content:encoded><![CDATA[<p>The aim of this study was to assess the sensitivity of distal biceps hook test &#8211; O&#8217;Driscoll hook test &#8211; in a retrospective series of acute and chronic distal biceps tendon tears and investigate the ability of the test to predict the need for graft reconstruction.</p>
<p> We retrospectively evaluated 234 consecutive distal biceps tendon tears&hellip;<span class="activity-read-more" id="activity-read-more-9569"><a href="https://www.catswannabecats.com/activity/p/9569/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9f8f768093fa40de7a9996c23476973e</guid>
				<title>Albrektsen Finnegan became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/9479/</link>
				<pubDate>Sat, 31 May 2025 22:44:45 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>